| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 01/21/2003 | US6509515 Transgenic mice expressing mutant human APP and forming congo red staining plaques |
| 01/21/2003 | US6509406 X-ray contrastable plastic materials comprising 0.1 wt. % to 25 wt. % of 4,4'-diiodobiphenyl. |
| 01/21/2003 | US6509324 Use as contrast agents in magnetic resonance imaging |
| 01/21/2003 | US6509004 Process for preparing contrast agents |
| 01/21/2003 | US6509002 Carbon 13 labeled lactic acid and carrier for parenteral or oral administration; measuring radioactivity level of exhaled carbon monoxide; accurate even in light cases where subject exhibits normal blood sugar levels at time of fasting |
| 01/21/2003 | US6509001 Calcitonin receptor binding reagents |
| 01/16/2003 | WO2003005026A2 Chemical capture reagent |
| 01/16/2003 | WO2003004466A2 Dye-sulfenates for dual phototherapy |
| 01/16/2003 | WO2003004062A1 Pharmaceutical formulations and ligands for use therein; mimetics for uea-1 |
| 01/16/2003 | WO2003003975A2 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 01/16/2003 | WO2002051301A3 Fullerene (c60)-based x-ray contrast agent for diagnostic imaging |
| 01/16/2003 | WO2002040540A3 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 01/16/2003 | WO2002020047A3 Chlamydial peptides and their mimics in demyelinating disease |
| 01/16/2003 | US20030013859 Use as contrast agents in magnetic resonance imaging |
| 01/16/2003 | US20030013759 Injection fatty acid, or salt thereof, into arteries |
| 01/16/2003 | US20030013733 Antihistamines, sleep disorders, central nervous system disorders |
| 01/16/2003 | US20030013642 Hemoglobin-haptoglobin complexes |
| 01/16/2003 | US20030013135 Spectrum analysis of macromolecules; obtain cell, expose to radio frequency, recover and analyze data |
| 01/16/2003 | US20030012735 Methods for diagnostic imaging by regulating the administration rate of contrast agent |
| 01/16/2003 | US20030012731 Monitoring radiation and/or metabolic activity in a subject. |
| 01/16/2003 | CA2452257A1 Pharmaceutical formulations and ligands for use therein; mimetics for uea-1 |
| 01/16/2003 | CA2449828A1 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 01/15/2003 | EP1275378A2 Particulate construct comprising polyhydroxyalkanoate and method for producing it |
| 01/15/2003 | EP1275373A1 Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof |
| 01/15/2003 | EP1274857A1 Inhibitor of differentiation knockout mammals and methods of use thereof |
| 01/15/2003 | EP1274710A2 Novel heteroaryl-diazabicycloalkanes |
| 01/15/2003 | EP1274466A1 Composition for detecting beta-1,3-glucan, preparation method thereof and diagnostic kit detecting beta-1,3-glucan |
| 01/15/2003 | EP1274465A2 Use of bile acid derivatives conjugated with metal ion chelated complexes for the diagnostic assessment of microvascular permeability |
| 01/15/2003 | EP0977597B1 Improved methods for diagnostic imaging using a contrast agent and a vasodilator |
| 01/15/2003 | EP0722442B1 Polyazacycloalkanes as dichelants |
| 01/14/2003 | US6506938 Process for the purifying of iopamidol |
| 01/14/2003 | US6506896 Conjugated to peptides, proteins, nucleic acids, antibodies, RNA, or DNA; medical diagnosis, electronics |
| 01/14/2003 | US6506881 Specific for human milk fat globule; complementarity determining region derived from variable domains of mouse monoclonal antibody |
| 01/14/2003 | US6506405 Methods and formulations of cremophor-free taxanes |
| 01/14/2003 | US6506156 Echogenic coating |
| 01/09/2003 | WO2003003009A1 Use of metal-ion chelates in validating biological molecules as drug targets in test animal models |
| 01/09/2003 | WO2003002610A1 Extracellular messengers |
| 01/09/2003 | WO2003002156A2 Contrast agents comprising metal particles encapsulated in microspheres for use in medical diagnostic imaging and therapy |
| 01/09/2003 | WO2003002145A1 Diagnosis and treatment of insulin-dependent diabetes mellitus and insulitis |
| 01/09/2003 | WO2003001907A1 Nmp35 apoptosis inhibitor gene disruptions compositions and methods related thereto |
| 01/09/2003 | WO2003001863A2 Novel endothelially expressed dnas and proteins, and their use |
| 01/09/2003 | WO2002004917A3 Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge |
| 01/09/2003 | WO2001062297A9 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/09/2003 | US20030009774 Trangenic rodent for use as model in evaluation of xenobiotics |
| 01/09/2003 | US20030009126 Resilient containers for hyperpolarized gases and associated methods |
| 01/09/2003 | US20030009104 In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease |
| 01/09/2003 | US20030008003 Compositions for enhanced absorption of NSAIDs |
| 01/09/2003 | CA2455654A1 Diagnosis and treatment of insulin-dependent diabetes mellitus and insulitis |
| 01/09/2003 | CA2452082A1 Extracellular messengers |
| 01/08/2003 | EP1272638A2 Drug metabolizing enzymes |
| 01/08/2003 | EP1272225A2 Lipid-based systems for targeting diagnostic agents |
| 01/08/2003 | EP1272223A1 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 01/08/2003 | EP1272222A2 Compositions for drug delivery |
| 01/08/2003 | EP1272221A2 Peptide conjugates for drug delivery |
| 01/08/2003 | EP1272161A2 Lipid-based drug delivery systems against parasitic infections |
| 01/08/2003 | EP1272160A2 Lipid-based drug delivery systems for topical application |
| 01/08/2003 | EP1098665B1 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 01/08/2003 | EP1095011A4 Novel fluorescent lanthanide chelates |
| 01/08/2003 | CN1098068C Container with multi-phase composition for use in diagnostic and therapeutic applications |
| 01/08/2003 | CN1098067C Method and apparatus for preparing liposomes precursor and liposomes with enhanced entrapment capacity, and its use |
| 01/07/2003 | US6503706 The invention addresses DNA-protein-complexes, proteins, DNA sequences and antibodies that are suitable for the detection of cells with an unlimited proliferation and tumor-formation potential. The invention further addresses methods for |
| 01/07/2003 | US6503478 Administering deuderated compound; spectrum analysis; applying electromagnetic waves, scanning |
| 01/07/2003 | US6503186 Radioactive seed with multiple markers and method for using same |
| 01/07/2003 | CA2164844C Methods of preparing gas-filled liposomes |
| 01/06/2003 | WO2003004559A1 Composite particles, derived conjugates, preparation method thereof and applications of same |
| 01/06/2003 | CA2445824A1 Composite particles, derived conjugates, preparation method thereof and applications of same |
| 01/03/2003 | WO2003001218A2 Macromolecular imaging agents for liver imaging |
| 01/03/2003 | WO2003000886A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/03/2003 | WO2003000869A1 Transgenic animals and cells expressing proteins necessary for susceptibility to hiv infection |
| 01/03/2003 | WO2003000864A2 Nucleic acid-associated proteins |
| 01/03/2003 | WO2003000859A2 G-protein coupled receptors |
| 01/03/2003 | WO2003000844A2 Protein modification and maintenance molecules |
| 01/03/2003 | WO2003000736A1 Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
| 01/03/2003 | WO2003000647A1 (ethylene)-(propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents |
| 01/03/2003 | WO2003000014A2 Spherical protein particles and methods of making and using them |
| 01/03/2003 | WO2002082972A9 Method and apparatus to optimize drug therapy |
| 01/03/2003 | WO2002060919A9 Molecules with extended half-lives, compositions and uses thereof |
| 01/03/2003 | WO2002036078A3 Targeting pluripotent stem cells to tissues |
| 01/03/2003 | WO2002032375A9 Uses of monoclonal antibody 8h9 |
| 01/03/2003 | WO2002004611A3 Aminoacyl trna synthetases |
| 01/03/2003 | WO2002002603A3 Protein modification and maintenance molecules |
| 01/03/2003 | WO2001098468A3 Proteases |
| 01/03/2003 | WO2001092528A3 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 01/03/2003 | CA2451185A1 Spherical protein particles and methods of making and using them |
| 01/03/2003 | CA2450969A1 Nucleic acid-associated proteins |
| 01/03/2003 | CA2450925A1 G-protein coupled receptors |
| 01/03/2003 | CA2450921A1 Protein modification and maintenance molecules |
| 01/03/2003 | CA2450828A1 Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
| 01/02/2003 | US20030004236 Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances |
| 01/02/2003 | US20030004153 Novel heteroaryl-diazabicycloalkanes |
| 01/02/2003 | US20030003511 Closure of bacterial ghost |
| 01/02/2003 | US20030003102 Morpholino imaging and therapy |
| 01/02/2003 | US20030003055 Shaking an aqueous solution comprising a phospholipid and a polymer, in the presence of a gas, at a temperature below the gel state to liquid crystalline transition temperature of the lipid |
| 01/02/2003 | US20030003054 Suitable for use as a contrast agent with a plurality of imaging modalities, including, for example, ultrasound, magnetic resonance imaging, and computed temography; neutron capture therapy |
| 01/02/2003 | US20030003052 Administering cholinergic agent; determining if elicits a cholinomimetic effect in the subject, as opposed to a cholinergic effect, thereby diagnosing of perturbation of autonomic nervous system |
| 01/02/2003 | US20030003050 Detecting a difference in an untranslated region of mRNA for a gene in which diversity in untranslated region of mRNA affects sensitivity to a drug, and evaluating sensitivity to a drug based on the detected difference |
| 01/02/2003 | EP1269207A1 A method for magnetic resonance imaging of the lung |
| 01/02/2003 | EP1268800A2 Mucin-1 specific binding members and methods of use thereof |
| 01/02/2003 | EP1268793A2 Fibroblast growth factor receptor-like molecules and uses thereof |
| 01/02/2003 | EP1268467A1 Heteroaromatic compounds having two-photon absorption activity |